No Data
No Data
Express News | GlaxoSmithKline's total revenue for the first quarter was £7.4 billion, up 10% year over year
Earnings Call Summary | GlaxoSmithKline(GSK.US) Q1 2024 Earnings Conference
The following is a summary of the GSK Plc (GSK) Q1 2024 Earnings Call Transcript:Financial Performance:GSK reported Q1 sales of £7.4 billion, a 13% increase, and a core operating profit of £2.4 billio
US stocks closed | The three major indices had mixed ups and downs, ultra-microcomputers fell more than 14%, and AMD fell nearly 9%
The S&P Index closed two consecutive losses, with Nvidia falling nearly 4%; Amazon closed up more than 2% and Starbucks fell nearly 16% after the earnings report.
Changes in US stocks | GlaxoSmithKline rose 2.3% Q1 results exceeded expectations and raised full-year profit guidelines
On May 1, GlaxoSmithKline (GSK.US) rose 2.36% to $42.42. GlaxoSmithKline's first-quarter revenue was £7.36 billion, up 10% year over year at a fixed exchange rate, higher than market expectations of £7.07 billion; earnings per share were 43.1 pence, higher than market expectations of 37.3 pence. GlaxoSmithKline raised its full-year profit guidelines. The adjusted earnings per share growth rate in 2024 is 8% to 10%, higher than the previous forecast of 6% to 9%; the revenue increase will reach the upper limit of the 5% to 7% forecast range. The company is ready to start in 2025
GlaxoSmithKline's Q1 performance exceeded expectations and raised annual profit guidelines and plans to launch 12 new products next year
GlaxoSmithKline, May 1 | GlaxoSmithKline announced first-quarter results. Revenue was £7.36 billion, up 10% year-on-year at a fixed exchange rate, higher than market expectations of £7.07 billion; earnings per share were 43.1 pence, higher than market expectations of 37.3 pence. The company raised its full-year profit guidelines. The adjusted earnings per share growth rate is expected to be 8% to 10% in 2024, higher than the previous forecast of 6% to 9%; the revenue increase will reach the upper limit of the forecast range of 5% to 7%. Company CEO Emma Walmsley's strategy focuses on strengthening vaccines and infectious disease medicines
GlaxoSmithKline Announces Strong Q1 and Positive 2024 Outlook
No Data